Alentis Therapeutics raised $181m in Series D funding co-led by OrbiMed, Novo Holdings, and Jeito Capital

Round investors: Bpifrance Morningside Ventures Jeito Capital Longitude Capital Novo A/S OrbiMed Advisors Piper Private Equity Pureos Bioventures RA Capital Management Catalio Capital Management Frazier Life Sciences Avego Bioscience Capital